RegImmune
Latest round
- Series E
Last raised
- May 2017
Total raised
- $40M
Investors
- 23
About RegImmune
RegImmune Corp.Founded in 2006 and headquartered in Tokyo, Japan, RegImmune Corp. specializes in therapies for immune disorders. The firm has successfully closed 7 deals to date, showcasing a strategic focus on the biopharmaceutical sector.REGiMMUNE focuses on innovative solutions for immune disorders, primarily through its core product offerings aimed at enhancing immune response and managing conditions such as graft-versus-host disease (GvHD). Their technology is designed to modulate the immune system, providing targeted therapies that address the underlying causes of immune dysregulation. The company's products are intended for healthcare providers and specialists treating patients with various immune-related conditions, thereby targeting a clientele that includes hospitals, clinics, and health systems across North America and Europe.REGiMMUNE's revenue is generated through strategic partnerships and collaborations within the biopharmaceutical sector, focusing on B2B transactions with healthcare providers and institutions. The company engages in direct sales and licensing agreements for its proprietary therapies, which are designed to address specific immune disorders. Revenue streams may include revenue from clinical trial agreements, product sales to healthcare facilities, and potential royalties from licensing arrangements. The company's flagship products, centered around immune modulation therapies, are structured to cater to a specialized market, reflecting the critical nature of the conditions they aim to treat.RegImmune Corp. The company aims to introduce new therapies for immune disorders over the next few years, targeting key markets in North America and Europe. Additionally, RegImmune is exploring opportunities to enter emerging markets in Asia by 2022, specifically focusing on partnerships that will enhance its distribution capabilities in these regions.
Who invested in RegImmune
23 investors across 7 rounds
See all investors in RegImmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
May 10, 2017
Amount
$5.7M
Investors
Series D
Feb 14, 2014
Amount
$9.2M
Investors
Series C
Feb 1, 2012
Amount
$5M
Investors
Series B
May 6, 2008
Amount
$8M
Investors
Series B
Feb 1, 2008
Amount
$6M
Investors
Series A
Feb 21, 2007
Amount
$4.2M
Investors
Seed
Aug 15, 2006
Amount
$1.6M
Investors
Questions about RegImmune
Who invested in RegImmune?
RegImmune has 23 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RegImmune raised?
RegImmune has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did RegImmune last raise money?
RegImmune's most recent round on record is a Series E, in May 2017.
What does RegImmune do?
RegImmune is a biotechnology company.
Where is RegImmune headquartered?
RegImmune is headquartered in Tokyo, Japan.
Which VCs invest in companies like RegImmune?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at RegImmune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like RegImmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.